Search

Your search keyword '"Dostalova Merkerova, Michaela"' showing total 39 results

Search Constraints

Start Over You searched for: Author "Dostalova Merkerova, Michaela" Remove constraint Author: "Dostalova Merkerova, Michaela"
39 results on '"Dostalova Merkerova, Michaela"'

Search Results

1. RUNX1 mutations contribute to the progression of MDS due to disruption of antitumor cellular defense: a study on patients with lower-risk MDS

2. Expression of circular RNAs in myelodysplastic neoplasms and their association with mutations in the splicing factor gene SF3B1

4. Aging-Related Gene Expression Signatures Define Likelihood of Disease Progression in Patients with Lower-Risk Myelodysplastic Syndromes

5. Upregulation of ZEB1-Derived Circular RNAs Is Associated with SF3B1-Mutated Myelodysplastic Neoplasms

11. Low Plasma Citrate Levels and Specific Transcriptional Signatures Associated with Quiescence of CD34+ Progenitors Predict Azacitidine Therapy Failure in MDS/AML Patients

14. LncRNA Profiling Reveals That the Deregulation of H19, WT1-AS, TCL6, and LEF1-AS1 Is Associated with Higher-Risk Myelodysplastic Syndrome

16. Circulating Small Noncoding RNAs Have Specific Expression Patterns in Plasma and Extracellular Vesicles in Myelodysplastic Syndromes and Are Predictive of Patient Outcome

18. RUNX1 Mutation Accompanied with Dysregulated Cellular Senescence in Lower-Risk Myelodysplastic Syndrome Patients Is Associated with Disease Progression

21. Differential Expression of MicroRNAs in CD34+ Cells of 5q- Syndrome

22. RUNX1mutations contribute to the progression of MDS due to disruption of antitumor cellular defense: a study on patients with lower-risk MDS

24. Relationship between Altered Gene Expression and DNA Methylation of the DLK1-DIO3 region in Azacitidine-Treated Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia with Myelodysplasia-Related Changes

25. Deregulated Expression of Long Noncoding RNAs H19, LEF1-AS1, TCL6, and WT1-AS1 Predicts Poor Outcome of Patients with Myelodysplastic Syndromes

27. Different Mutations in SF3B1Gene Have Specific Transcriptomic Characteristics in Myelodysplastic Neoplasms

31. Distinctive microRNA expression profiles in CD34+ bone marrow cells from patients with myelodysplastic syndrome.

33. Low Plasma Citrate Levels and Specific Transcriptional Signatures Associated with Quiescence of CD34 + Progenitors Predict Azacitidine Therapy Failure in MDS/AML Patients.

34. Circular RNAs in Myelodysplastic Syndromes and Impact of SF3B1Mutations on Their Expression

37. Deregulated Expression of Long Noncoding RNAs H19, LEF1-AS1, TCL6,and WT1-AS1Predicts Poor Outcome of Patients with Myelodysplastic Syndromes

38. Relationship between Altered Gene Expression and DNA Methylation of the DLK1-DIO3region in Azacitidine-Treated Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia with Myelodysplasia-Related Changes

39. Recurrent chromosomal breakpoints in patients with myelodysplastic syndromes and complex karyotype versus fragile sites.

Catalog

Books, media, physical & digital resources